EDNRA and diabetes mellitus: On the other hand ETA or dual ETA receptor antagonism have shown promising neuroprotective outcomes in diabetes, ischemia reperfusion injury and Aß1 induced cognitive dysfunction (Zhang et al., 2008; Papadopoulos et al., 2010; Briyal et al., 2011; Palmer and Love, 2011; Abdelsaid et al., 2014; Singh et al., 2014, 2016).